Latest Biotech News

Researchers publishing in Genome Medicine map spatial interactions between GPNMB+ macrophages and COL6A3+ fibroblasts that promote vascular fibrosis in glioblastoma. Using spatial transcriptomics,...

A Molecular Cancer study identifies the deubiquitylase USP7 as a regulator of immune signaling in microsatellite-stable colorectal cancer (MSS CRC). The authors show that USP7 activity suppresses...

Two transcriptome‑wide association studies (TWAS) reported independently uncover new genes causally linked to diabetic nephropathy. Teams used integrated genetic and expression datasets to...

A multicenter cohort study in the Journal of Ovarian Research reports sustained patient‑reported benefits for niraparib as long-term maintenance in platinum‑sensitive recurrent ovarian cancer....

AnswersNow closed a $40 million Series B led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures to expand access to autism therapy via its digital service. The...

Qiagen disclosed to advisers that it is evaluating strategic options amid reported interest from potential buyers, according to Bloomberg-sourced coverage; shareholders drove the stock back toward...

Moderna announced it is scaling back investments in vaccine trials, CEO comments reported on Bloomberg TV. The company cited growing political and public resistance in the U.S. to expanded vaccine...

Qiagen confirmed it is assessing strategic options after media reports that the company has held preliminary talks with potential buyers, including U.S. strategics. Bloomberg and other outlets...

Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research, extending consolidation among private-equity-backed contract research organizations (CROs). The deal highlights continued...

AnswersNow closed a $40 million Series B round led by HealthQuest Capital with participation from Left Lane Capital and Owl Ventures to scale access to autism therapy. The company provides remote...

A new study presents engineered CAR-T cells designed to exploit specific tumor characteristics to improve efficacy. Researchers detailed strategies that leverage tumor heterogeneity and...

A phase I clinical trial reported that infusions of natural killer (NK) cells produced promising safety and feasibility signals in patients with recurrent hepatocellular carcinoma after liver...

Updated results from the SPARK phase II cohort indicate responses to the combination of sitravatinib, a tyrosine-kinase inhibitor, with tislelizumab, an anti–PD-1 antibody, in patients with...

Researchers used transcriptome-wide association studies and genomic analyses to nominate novel causal genes linked to diabetic nephropathy. Two independent reports (Ma et al. and collaborators)...

A Nature Communications study introduced PGS-hub, a benchmarking platform comparing single-ancestry and multi-ancestry polygenic scores across traits and populations. The authors (Chen, Wang, Zhao...

A field commentary outlined four major trends shaping antibiotic resistance: faster diagnostics, targeted stewardship, novel therapeutic platforms, and policy-driven incentives for development....

Erasca (Nasdaq: ERAS) closed an upsized public offering, selling 25,875,000 shares at $10 to raise roughly $258.8 million. The proceeds will support the clinical-stage oncology company’s...

Bloomberg-reported interest has prompted Qiagen to evaluate strategic alternatives, including a potential sale, sending its shares higher. The life-science tools and diagnostics provider has held...

AnswersNow closed a $40 million Series B led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures, to expand access to its autism therapy platform. The funding...

Zarminali Pediatrics raised $110 million in a Series A led by Healthier Capital with participation from General Catalyst and K2 HealthVentures. The startup intends to use proceeds to scale...